We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sysmex and Siemens Extend Partnership in Hemostasis Testing

By LabMedica International staff writers
Posted on 26 May 2016
Sysmex Corporation (Kobe, Japan) and Siemens Healthcare Laboratory Diagnostics (NY, USA) have announced an extension to their long-standing partnership through at least 2020. The contract extension adds a minimum of two additional years to the global supply, distributorship, and sales and service agreement for hemostasis clinical testing products.

The partnership enables clinical laboratories around the world to continue to benefit from the large portfolio. The companies, which began collaborating over 20 years ago, also agreed to continue joint hemostasis product development activities that will streamline and optimize lab testing.

Siemens Healthcare and Sysmex provide products used to test for blood clotting disorders, preoperative bleeding risk management, and monitoring of patients on anticoagulant therapy medications. In the past few years alone, the companies have introduced several cutting-edge INNOVANCE reagents and multiple new platforms for various laboratory settings, including the recent worldwide launch of the Sysmex CS-2500 System, and the US launch of the Sysmex CS-5100 System with optional track-based automation. (The products are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed.)

The relationship extension was celebrated in April 2016 at Siemens AG headquarters in Munich (Germany). “We are pleased to extend our longstanding partnership with Siemens Healthcare,” said Hisashi Ietsugu, Chairman and CEO, Sysmex Corporation, “With the aging population, hemostasis testing has become even more important. Our partnership provides our customers with the innovative technologies needed to manage the increase in testing volumes, while providing accurate results for improved patient care.”

“The continued collaboration and 20-year partnership between Siemens and Sysmex is rare in the rapidly changing world of diagnostics,” said Franz Walt, President, Siemens Healthcare Laboratory Diagnostics, “As a leader in hemostasis testing, our combined mission to offer best-in-class solutions has enabled us to meet the needs of diverse laboratories throughout the world.”

Related Links:
Sysmex
Siemens Healthcare Laboratory Diagnostics

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Latest Industry News

ECCMID Congress Name Changes to ESCMID Global

Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform

Siemens to Close Fast Track Diagnostics Business